MedTrace Logo

Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

NCT01644799 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-01-30

No results posted yet for this study

Summary

Biologic therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Idelalisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase I trial studies the side effects and the best dose of lenalidomide when giving together with idelalisib in treating patients with recurrent follicular lymphoma.

Conditions

  • Recurrent Follicular Lymphoma

Interventions

DRUG

idelalisib

oral

DRUG

lenalidomide

oral

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gilead Sciences

    collaborator INDUSTRY

  • Celgene Corporation

    collaborator INDUSTRY

  • Alliance for Clinical Trials in Oncology

    lead OTHER

Principal Investigators

  • John P. Leonard, MD · Weill Medical College of Cornell University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-08-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01644799 on ClinicalTrials.gov